Intensity Therapeutics Inc

INTS

Company Profile

  • Business description

    Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

  • Contact

    1 Enterprise Drive
    Suite 430
    SheltonCT06484-4779
    USA

    T: +1 203 221-7381

    https://www.intensitytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    16

Stocks News & Analysis

stocks

Weekly earnings wrap: Last week’s winners & losers

A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks

Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount

Strong fourth quarter earnings.
stocks

Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies

We’ve raised our fair value estimate of Lilly stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.60104.20-1.15%
CAC 408,273.8411.680.14%
DAX 4024,721.46230.400.94%
Dow JONES (US)50,115.671,206.952.47%
FTSE 10010,369.7560.530.59%
HKSE26,559.95325.29-1.21%
NASDAQ23,031.21490.632.18%
Nikkei 22554,253.68435.640.81%
NZX 50 Index13,444.0223.27-0.17%
S&P 5006,932.30133.901.97%
S&P/ASX 2008,708.8096.70-1.10%
SSE Composite Index4,065.5810.33-0.25%

Market Movers